Spectral CT imaging of human osteoarthritic cartilage via quantitative assessment of glycosaminoglycan content using multiple contrast agents

Photon-counting detector CT - first experiences in the field of musculoskeletal radiology

The introduction of photon-counting detector CT (PCD-CT) marks a remarkable leap in innovation in CT imaging. The new detector technology allows X-rays to be converted directly into an electrical signal without an intermediate step via a scintillation layer and allows the energy of individual photons to be measured. Initial data show high spatial resolution, complete elimination of electronic noise, and steady availability of spectral image data sets. In particular, the new technology shows promise with respect to the imaging of osseous structures. Recently, PCD-CT was implemented in the clinical routine. The aim of this review was to summarize recent studies and to show our first experiences with photon-counting detector technology in the field of musculoskeletal radiology.We performed a literature search using Medline and included a total of 90 articles and reviews that covered recent experimental and clinical experiences with the new technology.In this review, we focus on (1) spatial resolution and delineation of fine anatomic structures, (2) reduction of radiation dose, (3) electronic noise, (4) techniques for metal artifact reduction, and (5) possibilities of spectral imaging. This article provides insight into our first experiences with photon-counting detector technology and shows results and images from experimental and clinical studies. · This review summarizes recent experimental and clinical studies in the field of photon-counting detector CT and musculoskeletal radiology.. · The potential of photon-counting detector technology in the field of musculoskeletal radiology includes improved spatial resolution, reduction in radiation dose, metal artifact reduction, and spectral imaging.. · PCD-CT enables imaging at lower radiation doses while maintaining or even enhancing spatial resolution, crucial for reducing patient exposure, especially in repeated or prolonged imaging scenarios.. · It offers promising results in reducing metal artifacts commonly encountered in orthopedic or dental implants, enhancing the interpretability of adjacent structures in postoperative and follow-up imaging.. · With its ability to routinely acquire spectral data, PCD-CT scans allow for material classification, such as detecting urate crystals in suspected gout or visualizing bone marrow edema, potentially reducing reliance on MRI in certain cases.. Bette S, Risch F, Becker J et al. Photon-counting detector CT - first experiences in the field of musculoskeletal radiology. Fortschr Röntgenstr 2024; DOI 10.1055/a-2312-6914.

The technical development of photon-counting detector CT

Since 1971 and Hounsfield's first CT system, clinical CT systems have used scintillating energy-integrating detectors (EIDs) that use a two-step detection process. First, the X-ray energy is converted into visible light, and second, the visible light is converted to electronic signals. An alternative, one-step, direct X-ray conversion process using energy-resolving, photon-counting detectors (PCDs) has been studied in detail and early clinical benefits reported using investigational PCD-CT systems. Subsequently, the first clinical PCD-CT system was commercially introduced in 2021. Relative to EIDs, PCDs offer better spatial resolution, higher contrast-to-noise ratio, elimination of electronic noise, improved dose efficiency, and routine multi-energy imaging. In this review article, we provide a technical introduction to the use of PCDs for CT imaging and describe their benefits, limitations, and potential technical improvements. We discuss different implementations of PCD-CT ranging from small-animal systems to whole-body clinical scanners and summarize the imaging benefits of PCDs reported using preclinical and clinical systems. KEY POINTS: • Energy-resolving, photon-counting-detector CT is an important advance in CT technology. • Relative to current energy-integrating scintillating detectors, energy-resolving, photon-counting-detector CT offers improved spatial resolution, improved contrast-to-noise ratio, elimination of electronic noise, increased radiation and iodine dose efficiency, and simultaneous multi-energy imaging. • High-spatial-resolution, multi-energy imaging using energy-resolving, photon-counting-detector CT has been used in investigations into new imaging approaches, including multi-contrast imaging.

Photon-Counting Detector CT for Musculoskeletal Imaging: A Clinical Perspective

Photon-counting detector (PCD) CT has emerged as a novel imaging modality that represents a fundamental shift in the way that CT systems detect x-rays. After pre-clinical and clinical investigations showed benefits of PCD CT for a range of imaging tasks, the U.S. FDA in 2021 approved the first commercial PCD CT system for clinical use. The technologic features of PCD CT are particularly well suited for musculo-skeletal imaging applications. Advantages of PCD CT compared with conventional energy-integrating detector (EID) CT include smaller detector pixels and excellent geometric dose efficiency that enable imaging of large joints and central skeletal anatomy at ultrahigh spatial resolution; advanced multienergy spectral postprocessing that allows quantification of gout deposits and generation of virtual noncalcium images for visualization of bone edema; improved metal artifact reduction for imaging of orthopedic implants; and higher CNR and suppression of electronic noise. Given substantially improved cortical and trabecular detail, PCD CT images more clearly depict skeletal abnormalities, including fractures, lytic lesions, and mineralized tumor matrix. The purpose of this article is to review, by use of clinical examples comparing EID CT and PCD CT, the technical features of PCD CT and their associated impact on musculoskeletal imaging applications.

Revealing the three-dimensional murine brain microstructure by contrast-enhanced computed tomography

To improve our understanding of the brain microstructure, high-resolution 3D imaging is used to complement classical 2D histological assessment techniques. X-ray computed tomography allows high-resolution 3D imaging, but requires methods for enhancing contrast of soft tissues. Applying contrast-enhancing staining agents (CESAs) ameliorates the X-ray attenuating properties of soft tissue constituents and is referred to as contrast-enhanced computed tomography (CECT). Despite the large number of chemical compounds that have successfully been applied as CESAs for imaging brain, they are often toxic for the researcher, destructive for the tissue and without proper characterization of affinity mechanisms. We evaluated two sets of chemically related CESAs (organic, iodinated: Hexabrix and CA4+ and inorganic polyoxometalates: 1:2 hafnium-substituted Wells-Dawson phosphotungstate and Preyssler anion), for CECT imaging of healthy murine hemispheres. We then selected the CESA (Hexabrix) that provided the highest contrast between gray and white matter and applied it to a cuprizone-induced demyelination model. Differences in the penetration rate, effect on tissue integrity and affinity for tissue constituents have been observed for the evaluated CESAs. Cuprizone-induced demyelination could be visualized and quantified after Hexabrix staining. Four new non-toxic and non-destructive CESAs to the field of brain CECT imaging were introduced. The added value of CECT was shown by successfully applying it to a cuprizone-induced demyelination model. This research will prove to be crucial for further development of CESAs for ex vivo brain CECT and 3D histopathology.

Latest advancements in imaging techniques in OA

The osteoarthritis (OA) research community has been advocating a shift from radiography-based screening criteria and outcome measures in OA clinical trials to a magnetic resonance imaging (MRI)-based definition of eligibility and endpoint. For conventional morphological MRI, various semiquantitative evaluation tools are available. We have lately witnessed a remarkable technological advance in MRI techniques, including compositional/physiologic imaging and automated quantitative analyses of articular and periarticular structures. More recently, additional technologies were introduced, including positron emission tomography (PET)-MRI, weight-bearing computed tomography (CT), photon-counting spectral CT, shear wave elastography, contrast-enhanced ultrasound, multiscale X-ray phase contrast imaging, and spectroscopic photoacoustic imaging of cartilage. On top of these, we now live in an era in which artificial intelligence is increasingly utilized in medicine. Osteoarthritis imaging is no exception. Successful implementation of artificial intelligence (AI) will hopefully improve the workflow of radiologists, as well as the level of precision and reproducibility in the interpretation of images.

Spectral computed tomography with inorganic nanomaterials: State-of-the-art

Recently, spectral computed tomography (CT) technology has received great interest in the field of radiology. Spectral CT imaging utilizes the distinct, energy-dependent X-ray absorption properties of substances in order to provide additional imaging information. Dual-energy CT and multi-energy CT (Spectral CT) are capable of constructing monochromatic energy images, material separation images, energy spectrum curves, constructing effective atomic number maps, and more. However, poor contrast, due to neighboring X-ray attenuation of organs and tissues, is still a challenge to spectral CT. Hence, contrast agents (CAs) are applied for better differentiation of a given region of interest (ROI). Currently, many different kinds of inorganic nanoparticulate CAs for spectral CT have been developed due to the limitations of clinical iodine (I)-based contrast media, leading to the conclusion that inorganic nanomedicine applied to spectral CT will be a powerful collaboration both in basic research and in clinics. In this review, the underlying principles and types of spectral CT techniques are discussed, and some evolving clinical diagnosis applications of spectral CT techniques are introduced. In particular, recent developments in inorganic CAs used for spectral CT are summarized. Finally, the challenges and future developments of inorganic nanomedicine in spectral CT are briefly discussed.